FibroBiologics Doses First Patients in Phase 1/2 Trial for Diabetic Foot Ulcers
FBLG is trading near its 52-week low of $0.86 (0.3% above the low).
Summary
FibroBiologics has begun dosing patients in its Phase 1/2 clinical trial for CYWC628, a treatment for diabetic foot ulcers. This marks a key operational milestone, transitioning the drug from the lab to human trials. The company also reported progress in manufacturing CYWC628 to support the ongoing trial. This positive clinical development comes amidst significant financial challenges, including a recent going concern warning and an active $7.5 million At-The-Market offering, as seen in recent SEC filings.
At the time of this announcement, FBLG was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.86 to $17.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.